Company intelligence / Profile preview

HMNC Brain Health

Munich, Germany

Ownership: Public · HMNC
Development stage: Other

Overview

HMNC Brain Health is advancing clinical precision psychiatry treatments, including novel therapies for major depressive disorder (MDD) and treatment-resistant depression (TRD), powered by genetic companion diagnostics. The company has shown promise in increasing treatment efficacy and reducing trial-and-error in psychiatric therapy, with several programs at Phase 2 clinical stage[2][1].

Therapeutic areas: Psychiatry
Modalities: Small moleculeBiologicCompanion diagnostic
Industry: Biotech

Beyond the preview

Go deeper on HMNC Brain Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HMNC Brain Health.

Explore the full profile